Obviously WS was not impressed that SUPG finally is profitable and also snagged a deal.

WS consideres SUPG dead money and it will sell off to $2 or even below in the next market correction, though the recent news should provide a floor at $2.

Very sad, the company had such promise before they screwed the European trial up. Incompetent mngt. will sink a biotech almost every time, or set them back for years.